Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients with Relapsed or Refractory High-Grade Myeloid Neoplasms

Status: Active


This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor peripheral blood cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells. Early stem cell transplantation may result in more successful treatment for patients with high-grade myeloid neoplasms.

Eligibility Criteria

Inclusion Criteria

  • Relapsed or refractory high-grade myeloid neoplasms, defined as having a blast count of >= 10% blasts at initial diagnosis; examples include excess blasts (EB)-2, with >= 10% blasts at initial diagnosis, acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML-2); standard definitions of relapse will apply (i.e., characterized by >= 5% abnormal blasts or blast equivalents as assessed by multiparameter flow cytometry or morphologic examination; peripheral blood blasts or blast equivalents; or extramedullary granulocytic sarcoma, per European LeukemiaNet [ELN] 2017 guidelines); bone marrow aspirate/biopsy will be accepted if performed outside University of Washington/Fred Hutchinson Cancer Research Center (UW/FHCRC); determination of disease status should occur within 30 days of signing informed consent * R/R high-grade myeloid neoplasm following intensive induction chemotherapy; relapsed high-grade myeloid neoplasm: patients will be classified as relapsed if they have >= 5% blasts after being in a complete remission (CR) following treatment for high-grade myeloid neoplasm; refractory high-grade myeloid neoplasm: patients may be classified as refractory if they have received at least one prior cycle of induction chemotherapy, whether with cladribine cytarabine mitoxantrone (GCLAM) or another regimen ** Patients may have received up to two courses of intensive induction chemotherapy during initial treatment prior to enrollment on this protocol; for example, patients who have received two courses of granulocyte colony stimulating factor (G-CSF) GCLAM (or similar) chemotherapy, with most recent high-dose cytarabine-containing chemotherapy > 6 months ago and CR lasting > 6 months, will be eligible for this protocol; regimens “similar to GCLAM” would include cytarabine at doses of 1g/m^2 for at least 5 doses; examples of regimens “similar to GCLAM” would be GCLA, fludarabine cytarabine granulocyte (FLAG), and FLAG-idarubicin (ida); however, patients who received more than two courses of GCLAM (or similar) chemotherapy, or patients who received two courses of GCLAM and had CR lasting < 6 months, would not be eligible * R/R high-grade myeloid neoplasm following less intensive induction chemotherapy. Patients who have received at least three cycles of treatment with a hypomethylating agent (HMA; such as azacitidine or decitabine) and still have >= 10% blasts will be eligible for the study (they will be considered refractory); similarly, patients who have received three or more cycles of HMA therapy who have had a response (e.g., achieving CR with < 5% blasts), but who then progress using standard definitions of relapse, will also be eligible (they will be considered relapsed)
  • Potentially eligible for reduced intensity conditioning based on known organ function (formal organ function testing may occur after consent)
  • Caregiver capable of providing post-HCT care
  • Written informed consent
  • Identified donor * Matched related or unrelated (one allele mismatch in HLA-A, B, or C OK) donor according to institutional standards * Unrelated volunteer donor who is mismatched with the recipient (i.e. 9/10 match)
  • Caregiver capable of providing post-HCT care, who will be present once induction therapy with filgrastim, cladribine, cytarabine, mitoxantrone hydrochloride (GCLAM) begins
  • Written informed consent for transplant
  • Either bone marrow or peripheral blood is allowed

Exclusion Criteria

  • Prior allogeneic HCT
  • More than two prior courses of induction chemotherapy
  • Relapse after minimal residual disease (MRD)-negative CR within 3 months of most recent GCLAM chemotherapy
  • Low likelihood of being eligible for reduced intensity conditioning HCT based on known information * Cardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmia, as assessed by multigated acquisition (MUGA) or transthoracic echocardiography (TTE) within previous 3 months and since the most recent anthracycline exposure * Corrected diffusing capacity of the lungs for carbon monoxide (DLCOc) < 40% or forced expiratory volume in 1 second (FEV1) < 50% * Estimated glomerular filtration rate (GFR) < 40 ml/min * Need for supplemental oxygen * Direct bilirubin or alanine aminotransferase (ALT) > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert’s disease or leukemic infiltration of hepatic parenchyma
  • Known human immunodeficiency virus (HIV) positivity
  • Pregnant or nursing (to be confirmed with quantitative human chorionic gonadotropin [HCG] testing)
  • Invasive solid tumor within 5 years; non-melanoma skin cancer or in situ malignancies are allowed
  • Evidence of serious uncontrolled infection
  • Eastern Cooperative Oncology Group (ECOG) of 3 or 4
  • Donor specific antibodies against donor HLA–DQ or –DP
  • Active bacterial, fungal or viral infections unresponsive to medical therapy
  • Active leukemia in the central nervous system (CNS)
  • HIV positive
  • Cardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmia
  • DLCOc < 40% or FEV1 < 50%
  • Estimated GFR < 40 ml/min
  • Need for supplemental oxygen
  • Direct bilirubin or ALT > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert’s disease or leukemic infiltration of hepatic parenchyma

Locations & Contacts


Fred Hutch / University of Washington Cancer Consortium
Status: Active
Contact: Mary-Elizabeth Muchmore Percival
Phone: 206-606-1320
Email: mperciva@seattlecca.org

Trial Objectives and Outline


I. To evaluate the feasibility of “early” allogeneic hematopoietic cell transplant (HCT) for patients with relapsed or refractory (R/R) high-grade myeloid neoplasms.


I. Estimate relapse-free survival (RFS), acute graft versus host disease (GVHD), treatment related mortality (TRM), event-free survival (EFS), overall survival (OS), and complete remission (with or without measurable disease) among patients who receive early HCT. Endpoints applicable to patients who don’t receive early transplant (survival endpoints and remission) will also be estimated for all patients enrolled on the study.

II. Assess factors that distinguish patients who receive early HCT from those who do not.

III. Compare RFS, EFS, OS, acute GVHD, and TRM between patients in the feasibility study and matched patients who were transplanted with standard scheduling.

IV. Demonstrate the feasibility of collecting patient-reported outcomes and resource utilization data for trial participants.

V. Describe the outcomes of patients enrolled who went on to allogeneic HCT off-study.


RE-INDUCTION CHEMOTHERAPY: Patients receive filgrastim subcutaneously (SC) on days 0-5, mitoxantrone hydrochloride intravenously (IV) over 60 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and cytarabine IV over 2 hours on days 1-5.

CONDITIONING REGIMEN: Beginning 14-60 days after re-induction chemotherapy, patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2, melphalan IV on days -3 to -2, cyclosporine orally (PO) twice daily (BID) on day -3. Sirolimus PO BID on day -3 will be given to patients who have matched unrelated donors or mismatched unrelated donors. Patients > 55 years or with significant co-morbidities will only receive melphalan IV on day -2 and will also receive total body irradiation (TBI) on day -1 or day 0.

EARLY TRANSPLANT: Patients undergo allogeneic HCT after conditioning regimen on day 0.

GVHD PROPHYLAXIS: Patients with matched donors will receive mycophenolate mofetil PO three times daily (TID) on days 0-30, then twice a day (BID) until day 40; and cyclosporine PO BID on days -3 to 96, with a taper until day 150. Patients with matched unrelated donors also receive sirolimus PO BID on days -3 to 150, with a taper until day 180. Patients with mismatched unrelated donors will receive mycophenolate mofetil PO TID on days 0-30, then BID until day 100, with a taper until day 150; cyclosporine PO BID on days -3 to 150, then taper until day 180; and sirolimus BID PO days -3 to 180, then a taper until day 365.

After completion of study treatment, patients are followed up periodically.

Trial Phase & Type

Trial Phase

Phase II

Trial Type


Lead Organization

Lead Organization
Fred Hutch / University of Washington Cancer Consortium

Principal Investigator
Mary-Elizabeth Muchmore Percival

Trial IDs

Primary ID 9567
Secondary IDs NCI-2016-00477, RG1016011
Clinicaltrials.gov ID NCT02756572